We Claim:

1. A method of inhibiting angiogenesis in an animal comprising administering to the animal an angiogenesis inhibiting amount of a composition comprising a serine protease and a pharmaceutically acceptable exccipient.

2. The method of Claim 1, wherein the serine protease is selected from the group consisting of kallikreins, human glandular kallikrein, pancreatic/renal kallikrein and prostate-specific antigen, or an antiangiogenic fragment thereof.

3. The method of Claim 2, wherein the prostate-specific antigen has the amino acid sequence as set forth in SEQ ID NO: 1, or an antiangiogenic fragment thereof.

4. The method of Claim 1, wherein the composition further comprises ANGIOSTATIN® protein.

5. The method of Claim 1, wherein the composition further comprises ENDOSTATIN® protein.

6. The method of Claim 1, wherein the animal has an angiogenesis-mediated disease selected from the group consisting of angiogenesis-dependent cancers; benign tumors; rheumatoid arthritis; psoriasis; ocular angiogenesis diseases; Osler-Webber Syndrome; myocardial angiogenesis; plaque neovascularization; telangiectasia; hemophiliac joints; angiofibroma; wound granulation; intestinal adhesions, atherosclerosis, scleroderma, hypertrophic scars, cat scratch disease and *Helicobacter pylori* ulcers.

7. A method of inhibiting cell proliferation comprising, administering to a cell undergoing proliferation a proliferation inhibiting amount of a composition comprising kallikrein to inhibit cell proliferation.

8. The method of Claim 8, wherein the cell proliferation is endothelial cell proliferation.

9. The method of Claim 7 wherein the serine protease is selected from the group consisting of kallikreins, human glandular kallikrein, pancreatic/renal kallikrein and prostate-specific antigen, or an antiangiogenic fragment thereof.

10. The method of Claim 7, wherein the prostate specific antigen has the amino acid sequence SEQ ID NO: 1, or an antiproliferative fragment thereof.

11. The method of Claim 7, wherein the composition further comprises ANGIOSTATIN® protein.

12. The method of Claim 7, wherein the composition further comprises ENDOSTATIN® protein.

13. The method of Claim 7, wherein the cell proliferation is related to an angiogenesis-mediated disease.

14. The method of Claim 13, wherein the angiogenesis-mediated disease is selected from the group consisting of angiogenesis-dependent cancers; benign tumors; rheumatoid arthritis; psoriasis; ocular angiogenesis diseases; Osler-Webber Syndrome; myocardial angiogenesis; plaque neovascularization; telangiectasia; hemophiliac joints; angiofibroma; wound granulation; intestinal adhesions, atherosclerosis, scleroderma, hypertrophic scars, cat scratch disease and *Helicobacter pylori* ulcers.

15. A method of diagnosing a disease or determining the prognosis of a disease mediated by angiogenesis comprising obtaining a biological sample and determining the levels of serine proteases in the sample.

16. The method of Claim 15 wherein the serine protease is selected from the group consisting of kallikreins, human glandular kallikrein, pancreatic/renal kallikrein and prostate-specific antigen, or an antiangiogenic fragment thereof.

17. The method of Claim 16 wherein the prostate-specific antigen has the amino acid sequence as set forth in SEQ ID NO: 1, or an anti-angiogenic fragment thereof.

18. The method of Claim 15 wherein the composition further comprises ANGIOSTATIN® protein.

19. The method of Claim 15 wherein the composition further comprises ENDOSTATIN® protein.

20. The method of Claim 15, wherein the angiogenesis-mediated disease is selected from the group consisting of angiogenesis-dependent cancers; benign tumors; rheumatoid arthritis; psoriasis; ocular angiogenesis diseases; Osler-Webber Syndrome; myocardial angiogenesis; plaque neovascularization; telangiectasia; hemophiliac joints; angiofibroma; wound granulation; intestinal adhesions, atherosclerosis, scleroderma, hypertrophic scars, cat scratch disease and *Helicobacter pylori* ulcers.